O’Melveny’s Representation of Shanghai Haohai Biological Technology in HKSE IPO Noted in Asian Legal Business

May 04, 2015

Asian Legal Business recently reported that O’Melveny & Myers advised biomedical materials producer Shanghai Haohai Biological Technology Co. in its US$302 million IPO on the Hong Kong Stock Exchange. Hong Kong partner Gigi Woo led the O’Melveny team that advised Shanghai Haohai, with support from Beijing partner Ke Geng.

Woo's practice focuses on equity and debt capital markets including Hong Kong and US IPOs. She also advises clients in a variety of general commercial and corporate finance transactions. Ke advises Chinese companies on corporate finance and M&A transactions, and advises clients in a wide range of industries on general corporate matters.